Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-01-2019 | Review Article

FDG PET/CT for assessing tumour response to immunotherapy

Report on the EANM symposium on immune modulation and recent review of the literature

Authors: Nicolas Aide, Rodney J. Hicks, Christophe Le Tourneau, Stéphanie Lheureux, Stefano Fanti, Egesta Lopci

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2019

Abstract

This paper follows the immunotherapy symposium held during the European Association of Nuclear Medicine (EANM) 2017 Annual Congress. The biological basis of the immune checkpoint inhibitors and the drugs most frequently used for the treatment of solid tumours are reviewed. The issues of pseudoprogression (frequency, timeline), hyperprogression and immune-related side effects are discussed, as well as their implications for patient management. A review of the recent literature on the use of FDG PET for assessment of immunotherapy is presented, and recommendations are provided for assessing tumour response and reporting immune-related side effects with FDG PET based on published data and experts’ experience. Representative clinical cases are also discussed.

Lheureux S, Denoyelle C, Ohashi PS, De Bono JS, Mottaghy FM. Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. Eur J Nucl Med Mol Imaging. 2017;44:41–54. https://doi.org/10.1007/s00259-017-3695-3.CrossRefPubMedPubMedCentral

Merelli B, Massi D, Cattaneo L, Mandala M. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol. 2014;89:140–65. https://doi.org/10.1016/j.critrevonc.2013.08.002.CrossRefPubMed

Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–9. https://doi.org/10.1038/nature10673.CrossRefPubMedPubMedCentral

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64. https://doi.org/10.1038/nrc3239.CrossRefPubMedPubMedCentral

Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1/2 pathway from discovery to clinical implementation. Front Immunol. 2016;7:550. https://doi.org/10.3389/fimmu.2016.00550.CrossRefPubMedPubMedCentral

Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39:98–106. https://doi.org/10.1097/coc.0000000000000239.CrossRefPubMedPubMedCentral

Vanpouille-Box C, Formenti SC, Demaria S. Toward precision radiotherapy for use with immune checkpoint blockers. Clin Cancer Res. 2018;24:259–65. https://doi.org/10.1158/1078-0432.CCR-16-0037.CrossRefPubMed

Cousin S, Italiano A. Molecular pathways: immune checkpoint antibodies and their toxicities. Clin Cancer Res. 2016;22:4550–5. https://doi.org/10.1158/1078-0432.Ccr-15-2569.CrossRefPubMed

Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28:2377–85. https://doi.org/10.1093/annonc/mdx286.CrossRefPubMed

10.

Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, et al. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018;36:638–46. https://doi.org/10.1007/s10637-017-0534-0.CrossRefPubMed

11.

Geukes Foppen MH, Rozeman EA, van Wilpe S, Postma C, Snaebjornsson P, van Thienen JV, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018;3:e000278. https://doi.org/10.1136/esmoopen-2017-000278.CrossRefPubMedPubMedCentral

12.

Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20. https://doi.org/10.1158/1078-0432.CCR-09-1624.CrossRefPubMed

13.

Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2017;23:1920–8. https://doi.org/10.1158/1078-0432.Ccr-16-1741.CrossRefPubMed

14.

Saada-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28:1605–11. https://doi.org/10.1093/annonc/mdx178.CrossRefPubMed

15.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67. https://doi.org/10.1056/NEJMoa1602252.CrossRefPubMedPubMedCentral

16.

Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34:1510–7. https://doi.org/10.1200/JCO.2015.64.0391.CrossRefPubMedPubMedCentral

17.

Sharon E. Can an immune checkpoint inhibitor (sometimes) make things worse? Clin Cancer Res. 2017;23:1879–81. https://doi.org/10.1158/1078-0432.Ccr-16-2926.CrossRefPubMedPubMedCentral

18.

Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143–52. https://doi.org/10.1016/s1470-2045(17)30074-8.CrossRefPubMedPubMedCentral

19.

Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773–82.CrossRefPubMed

20.

Sachpekidis C, Larribere L, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A, Hassel JC. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur J Nucl Med Mol Imaging. 2015;42:386–96. https://doi.org/10.1007/s00259-014-2944-y.CrossRefPubMed

21.

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122s–50s. https://doi.org/10.2967/jnumed.108.057307.CrossRefPubMed

22.

Kaira K, Higuchi T, Naruse I, Arisaka Y, Tokue A, Altan B, et al. Metabolic activity by (18)F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC. Eur J Nucl Med Mol Imaging. 2018;45:56–66. https://doi.org/10.1007/s00259-017-3806-1.CrossRefPubMed

23.

Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, et al. Prediction of response to immune checkpoint inhibitor therapy using early-time-point (18)F-FDG PET/CT imaging in patients with advanced melanoma. J Nucl Med. 2017;58:1421–8. https://doi.org/10.2967/jnumed.116.188839.CrossRefPubMedPubMedCentral

24.

Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC, et al. Absolute number of new lesions on (18)F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging. 2018;45:376–83. https://doi.org/10.1007/s00259-017-3870-6.CrossRefPubMed

25.

Sachpekidis C, Anwar H, Winkler J, Kopp-Schneider A, Larribere L, Haberkorn U, et al. The role of interim (18)F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging. 2018;45:1289–96. https://doi.org/10.1007/s00259-018-3972-9.CrossRefPubMed

26.

Kong BY, Menzies AM, Saunders CA, Liniker E, Ramanujam S, Guminski A, et al. Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell Melanoma Res. 2016;29:572–7. https://doi.org/10.1111/pcmr.12503.CrossRefPubMed

27.

Eshghi N, Lundeen TF, Kuo PH. Dynamic adaptation of tumor immune response with nivolumab demonstrated by 18F-FDG PET/CT. Clin Nucl Med. 2018;43:114–6. https://doi.org/10.1097/rlu.0000000000001934.CrossRefPubMed

28.

Grizzi F, Castello A, Lopci E. Is it time to change our vision of tumor metabolism prior to immunotherapy? Eur J Nucl Med Mol Imaging. 2018;45:1072–5. https://doi.org/10.1007/s00259-018-3988-1.CrossRefPubMed

29.

Higuchi M, Owada Y, Inoue T, Watanabe Y, Yamaura T, Fukuhara M, et al. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer. World J Surg Oncol. 2016;14:238. https://doi.org/10.1186/s12957-016-0998-y.CrossRefPubMedPubMedCentral

30.

Spigel DR, Chaft JE, Gettinger S, Chao BH, Dirix L, Schmid P, et al. FIR: efficacy, safety, and biomarker analysis of a phase II open-label study of atezolizumab in PD-L1-selected patients with non-small-cell lung cancer. J Thorac Oncol. 2018. https://doi.org/10.1016/j.jtho.2018.05.004.CrossRefPubMedPubMedCentral

31.

Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, et al. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging. 2016;43:1954–61. https://doi.org/10.1007/s00259-016-3425-2.CrossRefPubMed

32.

Takada K, Toyokawa G, Okamoto T, Baba S, Kozuma Y, Matsubara T, et al. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography. Cancer Med. 2017;6:2552–61. https://doi.org/10.1002/cam4.1215.CrossRefPubMedPubMedCentral

33.

Horne ZD, Jack R, Gray ZT, Siegfried JM, Wilson DO, Yousem SA, et al. Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res. 2011;171:1–5. https://doi.org/10.1016/j.jss.2011.03.068.CrossRefPubMed

34.

Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71. https://doi.org/10.1038/nature13954.CrossRefPubMedPubMedCentral

35.

Mazzaschi G, Madeddu D, Falco A, Bocchialini G, Goldoni M, Sogni F, et al. Low PD-1 expression in cytotoxic CD8(+) tumor-infiltrating lymphocytes confers an immune-privileged tissue microenvironment in NSCLC with a prognostic and predictive value. Clin Cancer Res. 2018;24:407–19. https://doi.org/10.1158/1078-0432.Ccr-17-2156.CrossRefPubMed

36.

Breki CM, Dimitrakopoulou-Strauss A, Hassel J, Theoharis T, Sachpekidis C, Pan L, et al. Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab. EJNMMI Res. 2016;6:61. https://doi.org/10.1186/s13550-016-0216-5.CrossRefPubMedPubMedCentral

37.

Rossi S, Toschi L, Castello A, Grizzi F, Mansi L, Lopci E. Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. Eur J Nucl Med Mol Imaging. 2017;44:2310–25. https://doi.org/10.1007/s00259-017-3802-5.CrossRefPubMed

38.

Tsai KK, Pampaloni MH, Hope C, Algazi AP, Ljung BM, Pincus L, et al. Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. J Immunother Cancer. 2016;4:58. https://doi.org/10.1186/s40425-016-0162-9.CrossRefPubMedPubMedCentral

39.

Wachsmann JW, Ganti R, Peng F. Immune-mediated disease in ipilimumab immunotherapy of melanoma with FDG PET-CT. Acad Radiol. 2017;24:111–5. https://doi.org/10.1016/j.acra.2016.08.005.CrossRefPubMed

40.

Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2:1346–53. https://doi.org/10.1001/jamaoncol.2016.1051.CrossRefPubMed

41.

Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018;4:374–8. https://doi.org/10.1001/jamaoncol.2017.2925.CrossRefPubMed

42.

Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJ. Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging. 2013;40:133–40. https://doi.org/10.1007/s00259-012-2247-0.CrossRefPubMed

43.

Lasnon C, Enilorac B, Popotte H, Aide N. Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs). EJNMMI Res. 2017;7:30. https://doi.org/10.1186/s13550-017-0279-y.CrossRefPubMedPubMedCentral

44.

Lasnon C, Majdoub M, Lavigne B, Do P, Madelaine J, Visvikis D, et al. (18)F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer. Eur J Nucl Med Mol Imaging. 2016;43:2324–35. https://doi.org/10.1007/s00259-016-3441-2.CrossRefPubMed

45.

Aide N, Lasnon C, Veit-Haibach P, Sera T, Sattler B, Boellaard R. EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging. 2017;44:17–31. https://doi.org/10.1007/s00259-017-3740-2.CrossRefPubMedPubMedCentral

Title: FDG PET/CT for assessing tumour response to immunotherapy
Report on the EANM symposium on immune modulation and recent review of the literature
Authors: Nicolas Aide
Rodney J. Hicks
Christophe Le Tourneau
Stéphanie Lheureux
Stefano Fanti
Egesta Lopci
Publication date: 01-01-2019
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2019
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-018-4171-4

ACC 2024 Congress

Springer Medicine

FDG PET/CT for assessing tumour response to immunotherapy

Report on the EANM symposium on immune modulation and recent review of the literature

Abstract

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

William T. O’Brien Sr. Top 3 Differentials in Radiology. A Case Review

18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System

68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy

Contribution of PET imaging to mortality risk stratification in candidates to lead extraction for pacemaker or defibrillator infection: a prospective single center study

Practice-based evidence for the clinical benefit of PET/CT—results of the first oncologic PET/CT registry in Germany

A prospective study of the feasibility of FDG-PET/CT imaging to quantify radiation-induced lung inflammation in locally advanced non-small cell lung cancer patients receiving proton or photon radiotherapy